层 地址：北京市朝阳区光华路正大中心北塔 11-12 邮编：100020 电话：010-65876666 传真：010-65876666-6 北京中银律师事务所 关于天津九安医疗电子股份有限公司 2025 年第四次临时股东大会之 法律意见书 二〇二五年十二月 法律意见书 北京中银律师事务所 关于天津九安医疗电子股份有限公司 2025 年第四次临时股东大会之 法律意见书 致：天津九安医疗电子股份有限公司 北京中银律师事务所（以下简称"本所"）接受天津九安医疗电子股份有限 公司（以下简称"公司"）的委托，指派见证律师出席公司 2025 年第四次临时 股东大会（以下简称"本次股东大会"）进行法律见证，并依据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）、 《上市公司治理准则》（以下简称"《治理准则》"）等法律、法规和规范性文 件以及《天津九安医疗电子股份有限公司章程》（以下简称"《公司章程》"） 的规定就公司本次股东大会的召集、召开程序、出席会议人员的资格、表决程序、 表决结果等有关事宜出具法律意见书。 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-102 天津九安医疗电子股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 公司于2025年12月15日召开了职工代表大会，形成如下决议： 经公司工会提名，与会职工代表选举丛明先生为公司第七届董事会职工代表 董事，与公司2025年第四次临时股东大会选举产生的非职工代表董事共同组成公 司第七届董事会，任期自本次职工代表大会审议通过之日起至公司第七届董事会 任期届满之日止。 丛明先生符合《公司法》《公司章程》规定的关于董事任职的资格和条件， 简历详见《第七届董事会第一次会议决议公告》（公告编号：2025-100）。本次 选举职工代表董事工作完成后，公司第七届董事会中兼任公司高级管理人员以及 由职工代表担任的董事人数总计未超过公司董事总数的二分之一，符合有关法律 法规、规范性文件及《公司章程》的规定。 特此公告。 天津九安医疗电子股份有限公司董事会 2025年12月16日 天津九安医疗电子股份有限公司(以下简称"公司"或"本公司")于2025年12月 15日召开20 ...

Core Points - The mercury thermometer will be discontinued starting January 1, leading to a surge in demand and price increases for existing mercury thermometers [1][2] - The price of mercury thermometers has significantly risen, with online prices reaching 15-20 yuan, and some exceeding 20 yuan, compared to previous prices of 2-10 yuan [1][2] - The alternative to mercury thermometers, non-mercury glass thermometers, are more expensive, costing 20-30 yuan, and are made with safer materials like gallium-indium-tin alloy [1][6] Industry Insights - The production of mercury thermometers in China was approximately 120 million units annually, resulting in over 10 tons of mercury needing disposal due to breakage [4] - Major manufacturers of non-mercury thermometers include Shanghai Huachen Medical Instrument Co., Yuyue Medical, and Jiuan Medical, with Shanghai Huachen being the largest producer [6] - The upstream suppliers for non-mercury materials include major metal producers such as China Aluminum (gallium), Zhuhai Group (indium), and Xiyang Silver Tin (tin) [6] Market Dynamics - The non-mercury thermometer market is limited and faces competition from electronic thermometers, which are also gaining popularity [7] - The safety and accuracy of gallium-indium-tin alloy thermometers are comparable to mercury thermometers, but they are positioned as a safer alternative [7] - Companies with capabilities in developing special alloy materials, such as Antai Technology and Yuyuan New Materials, are also noteworthy in this transition [6]

Group 1 - Anbotong plans to issue H-shares and list on the Hong Kong Stock Exchange, with the board authorizing management to start preparations within 12 months [1] - Xiangsheng Medical proposes a cash dividend of 3 yuan per 10 shares for the first three quarters of 2025 [2] - Junshi Biosciences receives FDA approval for clinical trials of JS212, a dual-specific antibody-drug conjugate for treating advanced solid tumors [3] Group 2 - Zhonghuan Environmental plans to raise up to 300 million yuan by issuing shares to a specific entity, with funds allocated for working capital and bank loan repayment [4] - Guao Technology announces a change in actual control to Xu Yinghui, with stock resuming trading on December 15 [5] - Jiaze New Energy intends to invest approximately 3.557 billion yuan in a green hydrogen and methanol project in Heilongjiang [6] Group 3 - Shanghai Airport reports a 15.47% year-on-year increase in passenger throughput at Pudong International Airport for November [7] - Innovent Biologics achieves primary endpoint in a Phase IIb study of Obinutuzumab for systemic lupus erythematosus, with plans for a Phase III trial [8] - Saiyi Information leads a national major science and technology project on intelligent manufacturing systems and robotics [9] Group 4 - Yipin Hong's Qinxing Qingjie oral solution is approved as a national second-level protected traditional Chinese medicine [10] - Yipin Hong's stake in US-based Arthrosi Therapeutics is set to be acquired by Sobi for a total of up to 950 million USD [11] - Pudong Jinqiao announces the resignation of Chairman Wang Ying due to job transfer [12] Group 5 - Jiaze New Energy plans to invest in two wind power projects with a total estimated investment of approximately 2.366 billion yuan [13] - Jinpan Technology receives approval from the CSRC for issuing convertible bonds to unspecified investors [14] - Zoli Pharmaceutical intends to acquire a multi-trace element injection asset group for 356 million yuan [15] Group 6 - Jiuan Medical's US subsidiary receives pre-market notification from the FDA for multiple testing products [16][17] - Changfei Optical Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [18] - Chenfeng Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [19][20][21][22]

Core Viewpoint - Multiple pharmaceutical companies announced positive developments, including FDA approvals and clinical trial advancements, indicating a favorable environment for the sector. Group 1: FDA Approvals and Clinical Trials - Ji'an Medical announced that its U.S. subsidiary received pre-market notification from the FDA for its quadrivalent home test kits for influenza A, influenza B, COVID-19, and RSV, allowing for normal sales in the U.S. market [1] - Junshi Biosciences reported that its EGFR/HER3 bispecific antibody-drug conjugate for treating advanced solid tumors received FDA approval for clinical trial application [1] - Innovent Biologics disclosed that its self-developed BTK inhibitor, Orelabrutinib, achieved the primary endpoint in a Phase II study for systemic lupus erythematosus and has been approved for Phase III registration clinical trials [1] Group 2: Strategic Partnerships and Product Developments - Yipinhong announced that its Qinxing Qingjie oral solution was approved as a national second-level protected traditional Chinese medicine. Additionally, the company secured a deal with Swedish pharmaceutical giant Sobi for $950 million (approximately 6.713 billion RMB) upfront and up to $550 million (approximately 3.887 billion RMB) in additional payments for a new URAT1 inhibitor, which has shown strong efficacy in dissolving gout stones and has received FDA fast track designation, with key Phase III clinical trials completed [1]

Group 1 - Multiple pharmaceutical stocks announced positive news, including Jiuan Medical's FDA pre-market notification for home test kits for influenza and COVID-19, allowing normal sales in the U.S. market [1] - Junshi Bioscience received FDA approval for clinical trials of its EGFR/HER3 bispecific antibody drug for treating advanced solid tumors [1] - Innovent Biologics' BTK inhibitor, Orelabrutinib, reached primary endpoints in a Phase II trial for systemic lupus erythematosus and has been approved for Phase III trials [2] Group 2 - The Chinese innovative drug industry is at a critical turning point, with over $100 billion in licensing deals in the first three quarters of 2025, indicating significant potential for domestic innovative drugs [3] - Major collaborations between Chinese companies and multinational corporations include a $12 billion deal between Hengrui and GSK, and a $114 billion potential deal between Innovent and Takeda [3] - The Chinese innovative drug sector is expected to show a compound annual growth rate of 20.2% from 2024 to 2028, with the market size projected to reach 26.9 billion yuan by 2028 [1][4] Group 3 - The pharmaceutical industry is anticipated to thrive by 2025, with the Hang Seng Index expected to double in value [4] - The innovative drug sector's listed companies achieved a total revenue of 48.83 billion yuan in the first three quarters of 2025, a 22% year-on-year increase, marking the first quarterly profit since inception [4] - The investment landscape is shifting from a focus on academic backgrounds and preclinical data to a stronger emphasis on companies' tangible strengths and product quality [4]

Core Insights - Multiple pharmaceutical companies have recently announced positive developments, indicating a potential growth phase in the industry [1][2][4]. Group 1: Company Announcements - Jiuan Medical's U.S. subsidiary received pre-market notification from the FDA for its home testing kits for multiple viruses, including COVID-19, allowing for normal sales in the U.S. market [1]. - Junshi Bioscience's dual-specific antibody drug for treating advanced solid tumors has received FDA approval for clinical trials [1]. - Innovent Biologics announced that its BTK inhibitor, Orelabrutinib, has met primary endpoints in a Phase II study for systemic lupus erythematosus and has been approved for Phase III trials [1]. - Yipinhong's Qinxiang Qingjie oral solution has been approved as a national secondary protected traditional Chinese medicine, and the company is set to receive up to $15 billion (approximately 67.13 billion RMB) from Sobi for a new URAT1 inhibitor [2]. Group 2: Market Trends - The Chinese innovative drug sector is experiencing a significant turnaround after a challenging period from 2021 to 2024, with total external licensing amounts surpassing $100 billion in the first three quarters of 2025 [4]. - Major collaborations between Chinese innovative drug companies and multinational corporations (MNCs) are on the rise, exemplified by significant deals such as the $12 billion partnership between Hengrui Medicine and GSK [4]. - The speed and cost-effectiveness of Chinese drug development are becoming competitive advantages, with drug discovery processes being 2-3 times faster than international counterparts [4]. Group 3: Financial Performance - The innovative drug sector in China reported a total revenue of 48.83 billion RMB in the first three quarters of 2025, reflecting a year-on-year growth of 22% [5]. - The sector achieved its first quarterly profit since its inception, with a net profit of 1.1 billion RMB in the third quarter [5]. Group 4: Investment Landscape - The capital market for Chinese innovative drugs is undergoing a transformation, shifting from a focus on academic backgrounds and preclinical data to a stronger emphasis on tangible product capabilities [6].

Core Viewpoint - iHealth Labs Inc., a subsidiary of the company, received pre-market notifications from the FDA for its multi-virus detection kits, indicating a significant expansion of its product offerings in the U.S. market [1][2]. Group 1: Product Development and Market Expansion - The iHealth four-in-one detection kit for influenza A, influenza B, COVID-19, and RSV has received FDA 510(k) pre-market notification, allowing it to be sold in the U.S. market [1][2]. - The three-in-one detection kit for influenza A, influenza B, and COVID-19 also received FDA 510(k) pre-market notification, which enhances its accuracy compared to previously authorized products under Emergency Use Authorization (EUA) [2]. - The transition from EUA to 510(k) ensures that the products can continue to be sold in the U.S. market even after the EUA is terminated, thus providing a stable regulatory framework for the company [2]. Group 2: Strategic Positioning and Market Demand - The company’s detection kits are positioned as regular home-use medical products for respiratory virus screening, reflecting strong consumer product characteristics [2][3]. - The company aims to meet the diverse needs of the U.S. market for respiratory virus screening, which is particularly relevant during the winter season when respiratory diseases are more prevalent [3]. - The company has expanded its sales channels beyond online platforms to include major retailers like Amazon, CVS, and Walmart, reducing reliance on government orders [3].

Core Viewpoint - Multiple pharmaceutical companies have announced positive developments, including FDA approvals and significant clinical trial milestones, indicating a robust growth trajectory in the pharmaceutical sector. Group 1: Company Announcements - Jiuan Medical announced that its U.S. subsidiary received FDA pre-market notifications for its four-in-one and three-in-one home testing kits for influenza and COVID-19, enhancing its product line in the IVD field [1][3]. - Junshi Biosciences reported that its dual-specificity antibody-drug conjugate (JS212) for treating advanced solid tumors received FDA approval for clinical trials [4]. - Innovent Biologics disclosed that its BTK inhibitor, Obutinib, achieved primary endpoints in a Phase II clinical trial for systemic lupus erythematosus and received approval for Phase III trials [4]. - Yipinhong announced that its Qinxing Qingjie oral solution was approved as a national secondary protected traditional Chinese medicine, which will strengthen its market position [5]. Group 2: Market Trends and Insights - The Chinese innovative drug industry is expected to experience rapid growth, with over $92 billion in outbound BD transactions in the first three quarters of 2025, indicating a significant opportunity for Chinese companies in the global market [7]. - The first version of the commercial health insurance innovative drug directory was released, highlighting the competitive landscape and the inclusion of several high-efficacy domestic drugs, which signals a positive trend for innovative drug development [8]. - Analysts suggest that the integration of innovative drugs into both medical insurance and commercial insurance will lead to rapid revenue growth for these products, benefiting patients and companies alike [8].

Core Viewpoint - Multiple pharmaceutical companies have announced positive developments, indicating a growing momentum in the industry and potential investment opportunities. Company Announcements - Jiuan Medical announced that its U.S. subsidiary received pre-market notifications from the FDA for several home and professional testing kits for influenza A, influenza B, COVID-19, and RSV, enhancing its product line in the IVD sector [2][3]. - Junshi Biosciences reported that its dual-specificity antibody-drug conjugate (JS212) for treating advanced solid tumors received FDA approval for clinical trials, marking a significant step in its oncology pipeline [4]. - Innovent Biologics disclosed that its BTK inhibitor, Orelabrutinib, achieved primary endpoints in a Phase IIb study for systemic lupus erythematosus and has been approved to proceed to Phase III trials, positioning it as a potential first-in-class treatment [4]. - Yipinhong announced that its Qinxing Qingjie oral solution has been approved as a national secondary protected traditional Chinese medicine, which will enhance its market competitiveness in pediatric medicine [5]. Industry Insights - The Chinese innovative drug industry is expected to experience rapid growth, with over $92 billion in outbound business development transactions in the first three quarters of 2025, indicating a significant expansion into the global market [6]. - The first commercial health insurance drug directory has been released, highlighting the competitive landscape for new drugs, with only 19 out of 121 new drugs passing the review, emphasizing the importance of clinical efficacy and innovation [7]. - The inclusion of innovative drugs in both medical insurance and commercial insurance is anticipated to lead to rapid revenue growth for these products, benefiting patients and driving growth for related pharmaceutical companies [7].